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ABSTRACT
Objective: Urinary tract infections (UTIs) are still commonly diagnosed in outpatients as well as in hospitalized patients. In this study, we 
investigated the prevalence and performed molecular characterization of extended-spectrum-β-lactamases (ESBL) and carbapenemases produced by 
Enterobacteriaceae isolates that cause community UTIs in Settat city, Morocco.
Methods: From January 2012 to December 2013, all uropathogenic community Enterobacteriaceae isolates were collected from the microbiology 
laboratory of Hassan II Hospital, Settat, Morocco. Antibiotic susceptibility testing was performed as recommended by Clinical and Laboratory 
Standard Institute. Phenotypic identification of ESBL and carbapenemase producer isolates was confirmed by the double-disk synergy test and the 
modified Hodge test, respectively. Molecular characterization of β-lactamase genes was performed using polymerase chain reaction (PCR), followed 
by sequencing of the obtained products.
Results: Among 153 isolates, 31 (20.26%) were multi-drug resistant (MDR). Nine strains (5.88%) were ESBL producers, of which Klebsiella 
pneumoniae (n=5; 20.83%), Escherichia coli (n=3; 3.15%), and Enterobacter cloacae (n=1; 9.09%) species were identified. The results of ESBL-
encoding gene detection by sequencing revealed the presence of CTX-M-15 (n=9) in association with other β-lactamase genes such as temoneira 1 
(n=8) and sulfhydryl variable 1 (n=5). According to the modified Hodge test and PCR, three isolates (1.96%) were positive carry the blaOXA-48 gene.
Conclusion: The emergence of MDR uropathogenic Enterobacteriaceae isolates in our community is highly alarming. Strict measures will be required 
to control the further spread of these uropathogenic isolates.
Keywords: Carbapenemase, Enterobacteriaceae, Extended-spectrum-β-lactamases, Moroccan community.
INTRODUCTION
Urinary tract infections (UTIs) are common bacterial infections that 
are still observed in outpatients and hospitalized patients [1]. They are 
the second most common infection appearing in the community [2]. 
Enterobacteriaceae are known to be the most common cause of 
UTIs [1]. Indeed, Escherichia coli and Klebsiella pneumoniae isolates 
are pathogens responsible for causing serious infections, both in the 
community and in health-care settings [3]. The past decade has shown 
an emergence of carbapenemase and extended-spectrum β-lactamase 
(ESBL) producing Enterobacteriaceae isolates in the community setting, 
the ESBLs being frequently plasmid encoded. These plasmids also carry 
genes encoding resistance to other antibiotics [4]. The majority of 
ESBL types are derived from temoneira (TEM) and sulfhydryl variable 
(SHV) genes by mutations. This extends the spectrum of beta-lactam 
antibiotics susceptible to hydrolysis by these enzymes are susceptible 
to hydrolysis by extended-spectrum antibiotics [4]. More than 180 TEM-
type and 130 SHV-type β-lactamases had been identified worldwide 
(www.lahey.org/Studies/). More recently, CTX-M enzymes that 
preferentially hydrolyze and confer resistance to cefotaxime have been 
found in several continents around the world. More than 100 CTX-M 
type β-lactamases have been identified (www.lahey.org/Studies/), 
divided into five groups (CTX-M-1, 2, 8, 9 and 25).
In Moroccan hospitals, E. coli and K. pneumoniae isolate producing 
carbapenemase and ESBL have been the most predominant [5,6]. The 
β-lactamase genes detected in Moroccan hospital isolates were blaCTX-M, 
blaTEM, blaSHV, blaDHA, and blaOXA types [5,7,8]. Carbapenemase OXA-48 
and NDM-1 producing Enterobacter cloacae, specifically K. pneumoniae, 
have been recently reported in Moroccan hospitals [5,7]. In addition, 
the occurrence of an OXA-48 producer in the environment has also been 
reported in Morocco [9].
Our study is known to be the first in Settat region, the objective of this 
study was to report the prevalence and characteristics of ESBL and 
carbapenemase-producing Enterobacteriaceae isolated from community 
acquired UTIs (CA-UTIs) in the Moroccan community of Settat city. 
It remains then, highly necessary to apply strict measures and adopt 
preventive strategies and continuous surveillance, to investigate the 
epidemiology of these multidrug-resistant organisms in the community.
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METHODS
Setting and bacterial isolates
From January 2012 to December 2013, urine specimens were collected 
from outpatients clinically suspected to have UTI, who had not 
previously been hospitalized. The urine specimens were analyzed at 
the microbiology laboratory at Hassan II Hospital, Settat. All urinary 
specimens with significant bacteremia (≥105 colony-forming unit/mL) 
were further processed. The isolates were identified by conventional 
methods and biochemical tests using the Api20E collection (Biomerieux, 
Marcy l’Etoile, France).
The gender and age of the patients were recorded. Enterobacteriaceae 
isolated from currently or previously hospitalized patients were 
excluded from the study.
Antimicrobial susceptibility testing
Antimicrobial drug susceptibility testing of Enterobacteriaceae isolates 
was performed according to the disk diffusion method on Mueller-
Hinton agar plates (Bio-Rad, Marnes-la-Coquette, France), and the 
results were interpreted according to the recommendations by the 
Clinical and Laboratory Standards Institute (CLSI) [10]. The following 
antimicrobial agents (Bio-Rad, Marnes-la-Coquette, France) were 
tested: Amoxicillin/clavulanic acid (20/10 µg), cephalothin (30 µg), 
cefoxitin (30 µg), cefotaxime (30 µg), ceftazidime (30 µg), ceftriaxone 
(30 µg), aztreonam (30 µg), ciprofloxacin (5 µg), gentamicin (10 µg), 
amikacin (30 µg), trimethoprim/sulfamethoxazole (1.25/23.75 µg), 
imipenem (10 µg), and ertapenem (10 µg).
Multi-drug resistant Enterobacteriaceae (MDRE) were defined as 
isolates that were non-susceptible to at least one agent in three or more 
antimicrobial categories [11]. Isolates that did not meet the criteria 
were described as non-MDRE.
Phenotypic detection of ESBL production
ESBL production was screened using a double-disk synergy test, 
between cefotaxime, ceftazidime, and aztreonam disks, placed at a 
distance of 30 mm (center to center) from the amoxicillin/clavulanic 
disk as previously described [12]. This test is considered as positive if 
a zone of inhibition is seen between the cephalosporin antibiotics and 
the amoxicillin/clavulanic disk, after 24 hrs of incubation. The standard 
strains E. coli ATCC 25922 and K. pneumoniae ATCC 700603 were used 
as a negative and a positive control for ESBL production.
Screening for carbapenemase production
All isolates showing reduced susceptibility to an imipenem disk 
(diameter of zone of inhibition <22 mm) or an ertapenem disk 
(diameter of zone of inhibition ≤21 mm) were screened for the 
production of carbapenemase according to the recommendations in 
the CLSI guidelines [10].
Phenotypic detection of carbapenemase
Phenotypic carbapenemase production was assessed using the modified 
Hodge test and interpreted according to the recommendations of the 
CLSI [10].
The phenotypic detection method for class B metallo-β-lactamase 
(MBL) production was performed using the combined disk test using 
two imipenem disks (10 µg), one containing 10 µL of 0.1 M (292 µg) 
anhydrous ethylene diamine tetra-acetic acid (EDTA) (Sigma Chemicals, 
St. Louis, MO), placed 25 mm apart (center to center). MBL production 
was considered positive if the difference in diameter between the 
inhibition zones with an imipenem disk supplemented with EDTA and 
an imipenem disk alone was >4 mm [12,13].
Preparation of DNA template for PCR
Total DNA was extracted by the boiling method by suspending a few 
colonies of an overnight culture of Enterobacteriaceae isolates growing 
on Luria-Bertani agar (Bio-Rad, Marnes-la-Coquette, France) in 500 µL 
of DNase- and RNase-free water (Invitrogen, Paisley, UK) and boiling at 
100°C for 10 minutes in a thermal block (Polystat 5, Bioblock Scientific, 
France), followed by centrifugation at 19,000 ×g for 5 minutes. An 
aliquot of 1 µL of the supernatant was used as the DNA template for 
PCR.
Detection of β-lactamase-encoding genes
Enterobacteriaceae isolates were screened by PCR for the following 
β-lactamase-encoding genes: blaCTX-M of phylogenetic lineage groups 1, 2 
and 9, blaTEM, blaSHV, blaPER, and blaVEB genes as described previously [6]. 
Carbapenem-resistant Enterobacteriaceae were tested by using specific 
primers for carabapenem-hydrolysing enzymes encoding the genes 
blaGES, blaKPC, blaVIM, blaIMP, blaOXA-48,and blaNDM as described previously [6].
Amplification reactions were performed in a volume of 50 µL containing 
1 µL of DNA template, 2.5 mM MgCl2, 0.4 µM each of the forward 
and reverse primers, 100 µM of each dNTP, and 2 units of Taq DNA 
polymerase (Promega, Madison, USA) in ×1 PCR buffer as provided by 
the manufacturer.
The cycling parameters were: 5 minutes of denaturation at 95°C; 
followed by 30 cycles of denaturation (95°C for 1 minute), annealing 
(52°C for 1 minute for TEM and IMP; 58°C for 1 minute for NDM; 60°C 
for 1 minute for CTX-M, KPC, VIM, and SHV), and extension (72°C for 
1 minute); ending with a final extension period of 72°C for 7 minutes.
PCR products were detected by electrophoresis on a 1.5% agarose 
gel (FMC Bioproduct, Rockland, USA) containing 1 µg/mL of ethidium 
bromide and analyzed under ultraviolet light. The gel picture was 
captured with an Olympus Digital Camera and analyzed using Digi-Doc-
it software (UVP, Upland, USA).
Sequencing of resistance genes
All obtained amplification products were sequenced to validate their 
identities. Both strands of the purified amplicons were sequenced with 
a Genetic Analyzer 3130 × 1 sequencer (Applied Biosystems, Foster 
City, CA, USA), with the same primers used for PCR amplification. The 
nucleotide and deduced protein sequences were analyzed using online 
software at the National Center for Biotechnology Information website 
(www.ncbi.nlm.nih.gov).
Statistical analysis
The Pearson’s χ2 or the Fisher’s exact tests were used (SPSS version 20 
software, IBM, Chicago, USA) for comparisons where appropriate. 
A p<0.05 was considered significant for all tests.
RESULTS
Among 1060 urine samples, 190 were positive for UTI, including 
153 (80.5%) that contained Enterobacteriaceae. Overall, 153 patients 
living in Settat city with Enterobacteriaceae-related CA-UTIs were 
recruited for this study. The strains were not duplicated. The mean 
patient age was 45 years (range 1-88 years, median 41 years), and the 
male/female ratio for these patients was 0.5.
The distribution of the bacteria in outpatients with and without MDRE 
UTIs is shown in Table 1. The majority of the uropathogens were 
E. coli (62.09%), K. pneumoniae (15.69%), Proteus mirabilis (9.80%), 
and E. cloacae (7.19%). E. coli was significantly more common in 
patients with non-MDRE UTIs than in those with MDRE UTIs (66.39% 
versus 45.16%; p=0.02), whereas K. pneumoniae and E. cloacae were 
significantly a more common in patients with MDRE UTIs than in those 
with non-MDRE UTIs (Table 1).
Antibiotic resistance rates for Enterobacteriaceae isolates are shown in 
Table 2.
The overall resistance rates for amoxicillin/clavulanic acid, 
sulfamethoxazole-trimethoprim, ciprofloxacin, cefoxitin, and gentamicin 
were 59.48%, 47.7%, 24.18%, 22.88%, and 18.30%, respectively. 
12 (7.84%) strains were resistant to the third-generation cephalosporins. 
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Seven strains (4.58%) were immediately susceptible to ertapenem. 
Antibiotic resistance rates for MDRE UTIs were significantly greater than 
for non-MDRE UTIs for the majority of the tested antibiotics (Table 3).
ESBL production was detected in nine (5.88%) Enterobacteriaceae 
isolates with a predominance of K. pneumoniae (n=5; 20.83%) followed 
by E. coli (n=3; 3.15%) and E. cloacae (n=1; 9.09%). The results of 
ESBL encoding gene detection by PCR revealed that the strains studied 
harbored a diversity of β-lactamases, namely CTX-M, SHV, and TEM 
(Table 4). Further analysis of the blaTEM, blaSHV and blaCTX-M sequences 
identified the respective subgroups TEM-1 (n=8), SHV-1 (n=5) and 
CTX-M-15 (n=9). No amplicons were obtained for the other two tested 
CTX-M subgroups (Table 4), blaPER and blaVEB were not detected in any 
of the isolates. All combinations of bla genes detected are shown in 
Table 4. Among the nine blaCTX-M-15 isolates, eight also harbored blaTEM-1 
and five harbored blaSHV genes. It is interesting to note that the three 
β-lactamases genes blaSHV, blaTEM and blaCTX-M were coexpressed in four 
K. pneumoniae isolates.
Table 1: Distribution of Enterobacteriaceae isolates with and without multidrug resistance isolated from 153 study patients
n (%)
Enterobacteriaceae Isolates All isolates MDR-isolates Non-MDR isolates p OR 95% CI
E. coli 95 (62.09) 14 (45.16) 81 (66.39) 0.02 0.41 0.18-0.92
K. pneumoniae 24 (15.69) 9 (29.03) 15 (12.30) 0.02 2.91 1.13-7.50
P. mirabilis 15 (9.80) 1 (3.23) 14 (11.48) 0.19 0.24 0.03-1.96
E. cloacae 11 (7.19) 5 (16.13) 6 (4.92) 0.03 3.71 1.05-13.11
C. freundii 7 (4.58) 2 (6.45) 5 (4.10) 0.57 1.61 0.29-8.74
K. oxytoca 1 (0.65) 0 1 (0.82) - - -
Total 153 (100) 31 (100) 122 (100) - - -
MDR: Multidrug resistant, Non-MDR: Non-multidrug resistant, OR: Odds ratio, CI: Confidence interval, E. coli: Escherichia coli, K. pneumoniae: Klebsiella pneumoniae, 
P. mirabilis: Proteus mirabilis, E. cloacae: Enterobacter cloacae, C. freundii: Citrobacter freundii, K. oxytoca: Klebsiella oxytoca
Table 2: Antibiotic resistance rates among Enterobacteriaceae species isolated from study patients












AMX 75 (78.95) - 13 (86.67) - - -
AMC 47 (49.47) 19 (79.17) 6 (40) - - 1 (100)
KF 39 (41.05) 19 (79.17) 5 (33.33) - - 1 (100)
CAZ 2 (2.11) 7 (29.17) 0 3 (27.27) 0 0
CTX 2 (2.11) 7 (29.17) 0 3 (27.27) 0 0
CRO 2 (2.11) 7 (29.17) 0 3 (27.27) 0 0
AZT 5 (5.26) 6 (25.00) 0 3 (27.27) 0 0
FOX 9 (9.47) 5 (20.83) 4 (26.67) - - 0
ERT 1 (1.05)  4 (16.67) 0 2 (18.18) 0 0
IPM 0 0 0 1 (9.09) 0 0
CIP 20 (21.05) 11 (45.83) 1 (6.67) 4 (36.36) 1 (14.29) 0
SXT 43 (45.26) 15 (62.50) 6 (40) 6 (54.55) 3 (42.86) 0
AK 1 (1.05) 2 (8.33) 0 0 0 0
GM 11 (11.58) 9 (37.50) 2 (13.33) 5 (45.45) 1 (14.29) 0
CT 0 0 - 2 (18.18) 1 (14.29) 0
AMX: Amoxicillin, AMC: Amoxicillin/clavulanic acid, KF: Cephalothin, CTX: Cefotaxime, CRO: Ceftriaxone, CAZ: Ceftazidime, AZT: Aztreonam, FOX: Cefoxitin, 
ERT: Ertapenem, IPM: Imipenem, CIP: Ciprofloxacin, SXT: Sulfamethoxazole/trimethoprim, AK: Amikacin, GM: Gentamicin and CT: Colistin, E. coli: Escherichia coli, 
K. pneumoniae: Klebsiella pneumoniae, P. mirabilis: Proteus mirabilis, E. cloacae: Enterobacter cloacae, C. freundii: Citrobacter freundii, K. oxytoca: Klebsiella oxytoca
Table 3: Antibiotic resistance rates among 153 unique Enterobacteriaceae bacterial isolates from study patients, with and without MDR
Antibiotics All isolates n (%) MDR n (%) non-MDR n (%) p OR 95% CI
AMX 131 (85.62) 30 (96.77) 101 (82.79) 0.12 3.11 0.69-14.07
AMC 91 (59.48) 26 (83.87) 65 (53.28) 0.001 4.56 1.64-12.65
KF 82 (53.59) 26 (83.87) 56 (45.90) 0.0003 5.10 1.96-13.29
CAZ 12 (7.84) 11 (35.48) 1 (0.82) >0.0001 66.55 8.14-544.06
CTX 12 (7.84) 11 (35.48) 1 (0.82) >0.0001 66.55 8.14-544.06
CRO 12 (7.84) 11 (35.48) 1 (0.82) >0.0001 66.55 8.14-544.06
AZT 14 (9.15) 14 (45.16) 0 >0.0001
FOX 35 (22.88) 16 (51.61) 19 (15.57) 0.0005 4.21 1.79-9.89
ERT 7 (4.58) 7 (22.58) 0 >0.0001
IPM 1 (0.65) 1 (3.23) 0 0.04
CIP 37 (24.18) 27 (87.10) 10 (8.20) >0.0001 75.60 22.02-259.51
SXT 73 (47.71) 29 (93.55) 44 (36.07) >0.0001 25.70 5.85-112.89
AK 3 (1.96) 3 (9.68) 0 0.00006
GM 28 (18.30) 19 (61.29) 9 (7.38) >0.0001 18.35 6.89-48.84
CT 3 (1.96) 0 3 (2.46) 1
AMX: Amoxicillin, AMC: Amoxicillin/clavulanic acid, KF: Cephalothin, CTX: Cefotaxime, CRO: Ceftriaxone, CAZ: Ceftazidime, AZT: Aztreonam, FOX: Cefoxitin, 
ERT: Ertapenem, IPM: Imipenem, CIP: Ciprofloxacin, SXT: Sulfamethoxazole/trimethoprim, AK: Amikacin, GM: Gentamicin, CT: Colistin, MDR: Multidrug resistant, 
Non-MDR: Non-multidrug resistant, OR: Odds ratio, CI: Confidence interval
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Among seven carbapenem-resistant isolates, three (3/153; 1.96%) 
were positive in the modified Hodge test and were identified as 
K. pneumoniae, E. coli, and E. cloacae. Only one carbapenemase-
producing isolate (E. coli E1) was an ESBL co-producer. The results of 
carbapenemase gene detection by PCR and sequencing revealed that 
the strains studied harbored the blaOXA-48 gene (Table 4).
DISCUSSION
Carbapenemase and ESBL-producing Enterobacteriaceae have 
become a worldwide problem. Enterobacteriaceae have become 
one of the most important causes of nosocomial and community-
acquired infections [14,15]. β-lactams (mainly extended-spectrum 
cephalosporins, carbapenems) and fluoroquinolones represent the main 
therapeutic option to treat infections due to these bacteria [2]. However, 
the extensive use of these antibiotics has caused both the emergence and 
the progressive spread of this health-threatening problem.
In Morocco, several studies demonstrate a wide dissemination of ESBLs 
in the environments, in both clinical and community settings [8,16,17], 
especially in community-acquired UTIs [16,18,19]. Most urinary 
and intra-abdominal infections with E. coli and K. pneumoniae are 
endogenous [20]. The ESBL producing Enterobacteriaceae showed a 
high frequency of resistance to various antimicrobial agents (β-lactams, 
ciprofloxacin, sulfamethoxazole trimethoprim, aztreonam) which have 
been reported increasingly worldwide [18,21]. E. coli and Klebsiella spp. 
producing β-lactamases play an important role in resistance to 
β-lactams [22]. The mechanism of resistance to the third-generation 
cephalosporins in non-ESBL producers could be due to the production 
of AmpC β-lactamase [23].
Our study reveals a higher prevalence of ESBL-producing K. pneumoniae 
(20.83%) and ESBL-producing E. coli (3.26%) in the Moroccan 
community than recorded in previous Moroccan reports [18].
This indicates that in a 2-year interval, the prevalence of ESBLs 
among urinary K. pneumoniae has been increasing, and shows 
that ESBL-producing strains continue to disseminate in Moroccan 
communities.
The inappropriate and extensive use of broad-spectrum antibiotics 
can lead to the emergence and spread of these ESBL producing 
strains. Another cause remains a person-to-person transmission via 
fecal carries between within families as reported by Rodriguez-Bano 
et al. [24]. Furthermore, evidence of ESBL-producing isolates in cattle, 
poultry, dogs, and cats suggests that food-producing animals and house 
pets might act as a reservoir for the transmission or acquisition of ESBL 
genes or ESBL-producing Enterobacteriaceae in the community [25,26]. 
Furthermore, antibiotics are commonly used in animals for prophylaxis 
or as performance enhancers, and such practices are likely to increase 
the development of resistance.
In general, the resistance patterns of ESBL-producing bacteria studied 
here were similar to those frequently described in various studies, 
i.e., the ESBL producers were resistants to β-lactams, fluoroquinolones, 
aminoglycosides and trimethoprim/sulfamethoxazole [18,26], which 
contributes to the selection and persistence of multidrug-resistant 
ESBL strains and plasmids in both clinical and community settings.
We detected a variety of β-lactamases among Enterobacteriaceae isolates, 
namely SHV-, CTX-M-, and TEM-type enzymes. The CTX-M type was 
the most common ESBL in our setting [16,19]. The predominance of 
CTX-M-15 indicates that this variant is now common in Morocco, as in 
other countries, as a result of worldwide dissemination [27,28]. The higher 
incidence of CTX-M among ESBL enzymes is probably associated with the 
mobilization and incorporation of blaCTX-M into mobile genetic elements. 
Cantón et al. report that blaCTX-M genes have been mobilized to plasmids 
almost ten times more frequently than other class A β-lactamases [29].
The coexistence of different β-lactamase genes within the same isolate, 
as found in this study, has also been reported in other countries [30,31]. 
Although the clinical importance of ESBLs in patients carrying ESBL-
expressing K. pneumoniae is clear, the clinical importance of non-ESBL 
enzymes is yet to be revealed. Among these non-ESBL enzymes, we 
identified SHV-1, an intrinsic gene in K. pneumoniae. Co-expression of 
CTX-M enzymes and SHV-1 penicillinases is most commonly found in 
K. pneumoniae isolates [32,33].
The OXA-48-producing Enterobacteriaceae isolates described in 
Moroccan communities and hospitals may have a relationship to those 
identified in France and the Netherlands [9].
This report illustrates the widespread of carbapenemase-producing 
Enterobacteriaceae in the Mediterranean area and in Europe. Our 
search showed trends of the emergence of carbapenem-resistant 
Enterobacteriaceae in Moroccan community settings along with the 
carriage of resistance genes with clinical relevance coexpressed by 
blaOXA-48 [18]. The spread of the same major carrying plasmid between 
Moroccan cities has been identified. This finding emphasizes the 
importance of systematic detection to contain the spread of these 
multidrug-resistant organisms.
CONCLUSION
Our study reported an increase in the prevalence of ESBL and OXA-48 
carbapenemase-producing multidrug-resistant Enterobacteriaceae 
in Morocco. These data suggest that specific strategies for regular 
surveillance and control of antimicrobial resistance agents are required. 
Antibiotic resistance remains a serious issue, as the rapid spread of 
these bacteria would eventually limit clinical treatment choices. To 
avoid UTI treatment failures, it will be necessary to start monitoring 
ESBL and carbapenemase producers in laboratories using conventional 
antibiograms.
Table 4: Characteristics of the ESBL-producing Enterobacteriaceae isolates collected from a Moroccan community
Code Species Date of isolation 
(DD/MM/YYY)
Gender/age β-lactamase Carbapenemase type Antibiotic 
resistance pattern*
Ec1 E. cloacae 11/04/2012 M/65 - OXA-48 FOX, ERT, SXT, CIP, GM
Ec2 E. cloacae 07/10/2013 M/60 CTX-M-15, TEM-1 FOX, ERT, SXT, CIP, GM
E1 E. coli 04/04/2012 M/60 CTX-M-15, TEM-1 OXA-48 FOX, SXT, GM
E2 E. coli 27/06/2012 M/60 CTX-M-15, TEM-1 FOX, SXT, CIP
E3 E. coli 17/12/2013 M/65 CTX-M-15, TEM-1 FOX, SXT, CIP, GM
K1 K. pneumoniae 16/01/2013 F/70 OXA-48 FOX, SXT, CIP
K2 K. pneumoniae 26/01/2012 M/64 CTX-M-15, TEM-1, SHV-1 FOX, SXT, CIP, GM
K3 K. pneumoniae 01/06/2013 M/50 CTX-M-15, TEM-1, SHV-1 SXT, CIP, GM
K4 K. pneumoniae 02/10/2013 M/65 CTX-M-15, TEM-1, SHV-1 FOX, ERT, SXT, CIP, GM
K5 K. pneumoniae 09/11/2012 M/65 CTX-M-15, TEM-1, SHV-1 SXT, CIP, GM
K6 K. pneumoniae 11/12/2012 M/66 CTX-M-15, SHV-1 SXT, CIP, GM
*All isolates were resistant to amoxicillin, amoxicillin/clavulanic acid, cephalothin, cefotaxime, ceftriaxone, ceftazidime and aztreonam. M: Male, F: Female, 
FOX: Cefoxitin, ERT: Ertapenem, SXT: Sulfamethoxazole/trimethoprim, CIP: ciprofloxacin, GM: Gentamicin, E. coli: Escherichia coli, K. pneumoniae: Klebsiella pneumoniae, 
P. mirabilis: Proteus mirabilis, E. cloacae: Enterobacter cloacae, C. freundii: Citrobacter freundii, K. oxytoca: Klebsiella oxytoca, ESBL: Extended-spectrum-β-lactamases
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